Published in Can J Gastroenterol on December 01, 2010
Cost-effectiveness of screening for hepatitis C in Canada. CMAJ (2015) 1.16
The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol (2013) 0.96
Mortality among British Columbians testing for hepatitis C antibody. BMC Public Health (2013) 0.94
Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol (2011) 0.94
Direct cost associated with acquired brain injury in Ontario. BMC Neurol (2012) 0.86
A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada. Subst Abuse Treat Prev Policy (2013) 0.84
Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med (2015) 0.82
A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada. Subst Abuse Treat Prev Policy (2014) 0.81
A cost-benefit/cost-effectiveness analysis of an unsanctioned supervised smoking facility in the Downtown Eastside of Vancouver, Canada. Harm Reduct J (2014) 0.80
Pay now or pay (more) later: tracking the costs of hepatitis C infection. Can J Gastroenterol (2010) 0.79
Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a population-based study. J Am Heart Assoc (2015) 0.79
Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open (2017) 0.78
Reasons for Nonattendance across the Hepatitis C Disease Course. ISRN Nurs (2013) 0.78
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol (2004) 7.20
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med (2006) 3.87
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health (2001) 3.46
Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care (1999) 3.15
Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology (2008) 2.66
Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology (2003) 2.05
Prediction of hepatitis C burden in Canada. Can J Gastroenterol (2000) 1.97
The direct costs of HIV/AIDS care. Lancet Infect Dis (2006) 1.87
Estimating the treatment costs of breast and lung cancer. Med Care (1991) 1.80
The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol (2008) 1.46
A comparison of several regression models for analysing cost of CABG surgery. Stat Med (2003) 1.31
The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ (2003) 1.30
Measuring costs: administrative claims data, clinical trials, and beyond. Med Care (2002) 1.16
Costs of hepatitis C. Arch Intern Med (2001) 1.10
Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS (2005) 1.05
Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol (2005) 1.05
Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol (2004) 1.00
Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS (2005) 0.97
Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin (2004) 0.92
Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population. J Viral Hepat (2000) 0.83
Histological improvement of chronic liver disease after spontaneous serum hepatitis C virus clearance. J Med Virol (2003) 0.78
Health care costs of persons with newly diagnosed hepatitis C virus: a population-based, observational study. J Viral Hepat (2008) 0.78
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol (2014) 4.31
Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP). BMJ (2011) 3.81
Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA (2010) 2.61
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. Int J Cancer (2010) 2.18
A practical approach to evidence-based dentistry: IX: how to appraise and use an article about economic analysis. J Am Dent Assoc (2015) 1.99
Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine (2010) 1.91
Hospitalizations and emergency department visits for TBI in Ontario. Can J Neurol Sci (2010) 1.90
Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol (2012) 1.90
Lack of comprehension of common prostate cancer terms in an underserved population. J Clin Oncol (2009) 1.82
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology (2010) 1.80
The effect of English language proficiency on length of stay and in-hospital mortality. J Gen Intern Med (2004) 1.80
Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) (2011) 1.79
Hope and probability: patient perspectives of the meaning of numerical information in cancer communication. Qual Health Res (2006) 1.70
Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf (2011) 1.69
Comparative operative outcomes of early and delayed cholecystectomy for acute cholecystitis: a population-based propensity score analysis. Ann Surg (2014) 1.65
Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int (2009) 1.62
The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One (2012) 1.58
Utility-based Quality of Life measures in Alzheimer's disease. Qual Life Res (2006) 1.55
The Canadian STOP-PAIN project - Part 2: What is the cost of pain for patients on waitlists of multidisciplinary pain treatment facilities? Can J Anaesth (2010) 1.54
Coverage with evidence development: the Ontario experience. Int J Technol Assess Health Care (2011) 1.53
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53
The mortality benefit of direct trauma center transport in a regional trauma system: a population-based analysis. J Trauma Acute Care Surg (2012) 1.46
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
Early prevention of pressure ulcers among elderly patients admitted through emergency departments: a cost-effectiveness analysis. Ann Emerg Med (2011) 1.43
Acute appendicitis in young children: cost-effectiveness of US versus CT in diagnosis--a Markov decision analytic model. Radiology (2008) 1.39
Ethnic differences in perception of lung function: a factor in pediatric asthma disparities? Am J Respir Crit Care Med (2010) 1.36
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.34
Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection. PLoS One (2011) 1.32
Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine (2011) 1.31
Preventing pressure ulcers in long-term care: a cost-effectiveness analysis. Arch Intern Med (2011) 1.25
Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med (2010) 1.19
Issues and methods in disparities research: the Rhode Island-Puerto Rico asthma center. Pediatr Pulmonol (2009) 1.19
Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol (2011) 1.18
Conundrums in childhood asthma severity, control, and health care use: Puerto Rico versus Rhode Island. J Allergy Clin Immunol (2009) 1.17
Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. Value Health (2012) 1.16
Comparative economic analyses of patient safety improvement strategies in acute care: a systematic review. BMJ Qual Saf (2012) 1.14
Cost effectiveness of screening immigrants for hepatitis B. Liver Int (2011) 1.12
Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Med Decis Making (2012) 1.12
Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. J Clin Epidemiol (2005) 1.09
Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol (2005) 1.08
Development of measures of the quality of emergency department care for children using a structured panel process. Pediatrics (2006) 1.06
Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med (2007) 1.05
Pressure ulcer multidisciplinary teams via telemedicine: a pragmatic cluster randomized stepped wedge trial in long term care. BMC Health Serv Res (2014) 1.03
Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol (2011) 1.03
'Being known': patients' perspectives of the dynamics of human connection in cancer care. Psychooncology (2005) 1.02
Effectiveness of emergency department asthma management strategies on return visits in children: a population-based study. Pediatrics (2007) 1.02
Changes in health utilities and health-related quality of life over 12 months following radical prostatectomy. Can Urol Assoc J (2009) 1.01
Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys (2005) 1.01
The magnitude, share and determinants of unpaid care costs for home-based palliative care service provision in Toronto, Canada. Health Soc Care Community (2013) 1.00
Survival of the fittest: the hidden cost of undertriage of major trauma. J Am Coll Surg (2010) 0.99
Canadian Outcomes Study in Dementia: study methods and patient characteristics. Can J Psychiatry (2004) 0.98
Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol (2012) 0.97
Gender-associated differences in access to trauma center care: A population-based analysis. Surgery (2012) 0.97
Microbial contamination and chemical toxicity of the Rio Grande. BMC Microbiol (2004) 0.95
Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada. Value Health (2010) 0.95
HCV co-infection in HIV positive population in British Columbia, Canada. BMC Public Health (2010) 0.95
Psychosocial and clinical correlates of suicidal acts: results from a national population survey. Br J Psychiatry (2008) 0.94
Content validity for dementia of three generic preference based health related quality of life instruments. Qual Life Res (2002) 0.93
Impact of varicella vaccination on health care outcomes in Ontario, Canada: effect of a publicly funded program? Vaccine (2008) 0.93
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord (2004) 0.93
Modeling factors influencing the demand for emergency department services in Ontario: a comparison of methods. BMC Emerg Med (2011) 0.92
Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol (2008) 0.92
Feasibility of internet-based health-related quality of life data collection in a large patient cohort. J Med Internet Res (2010) 0.92
A review of interventions triggered by hepatitis A infected food-handlers in Canada. BMC Health Serv Res (2006) 0.91
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum (2003) 0.91
Specialized multi-disciplinary heart failure clinics in Ontario, Canada: an environmental scan. BMC Health Serv Res (2012) 0.91
Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists. Can J Gastroenterol (2003) 0.91
Health technology assessment: a comprehensive framework for evidence-based recommendations in Ontario. Int J Technol Assess Health Care (2009) 0.90
Predictors of family caregiver ratings of patient quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study. Am J Geriatr Psychiatry (2011) 0.90
Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics (2008) 0.89
Institutional and provider factors impeding access to trauma center care: an analysis of transfer practices in a regional trauma system. J Trauma Acute Care Surg (2012) 0.89
The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making (2008) 0.89
Prescribing patterns for Alzheimer disease: survey of Canadian family physicians. Can Fam Physician (2006) 0.89
The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol (2010) 0.89
Cost variations in ambulatory and home-based palliative care. Palliat Med (2010) 0.88
Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int (2008) 0.88
Factors associated with discharge destination from acute care after acquired brain injury in Ontario, Canada. BMC Neurol (2012) 0.88
Vaccines in the public eye. Nat Med (2005) 0.87
Evaluating the ability to detect change of health-related quality of life in children with Hodgkin disease. Cancer (2010) 0.87
A population-based analysis of the clinical course of 10,304 patients with acute cholecystitis, discharged without cholecystectomy. J Trauma Acute Care Surg (2013) 0.87
Acute care alternate-level-of-care days due to delayed discharge for traumatic and non-traumatic brain injuries. Healthc Policy (2012) 0.87
Predictors of patient self-ratings of quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study. Am J Geriatr Psychiatry (2011) 0.87
Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer. Value Health (2013) 0.87
Early economic evaluation of emerging health technologies: protocol of a systematic review. Syst Rev (2014) 0.86
Comparing cancer care, outcomes, and costs across health systems: charting the course. J Natl Cancer Inst Monogr (2013) 0.86
Direct cost associated with acquired brain injury in Ontario. BMC Neurol (2012) 0.86
A population-based study to evaluate the effectiveness of multidisciplinary heart failure clinics and identify important service components. Circ Heart Fail (2012) 0.86
Are stentless valves hemodynamically superior to stented valves? Long-term follow-up of a randomized trial comparing Carpentier-Edwards pericardial valve with the Toronto Stentless Porcine Valve. J Thorac Cardiovasc Surg (2010) 0.86
Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma. Anticancer Drugs (2010) 0.85
A population-based analysis of the discrepancy between potential and realized access to trauma center care. Ann Surg (2013) 0.85
Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol (2012) 0.85
Methadone use in relation to hepatitis C virus testing in British Columbia. Can J Public Health (2011) 0.84
Economic appraisal of a community-wide cardiovascular health awareness program. Value Health (2013) 0.84
Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy. Cancer (2010) 0.84
The effect of hepatitis C virus infection on health-related quality of life in prisoners. J Urban Health (2006) 0.84